Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

RR Razonable, C Pawlowski, JC O'Horo, LL Arndt… - …, 2021 - thelancet.com
Background Real-world clinical data to support the use of casirivimab–imdevimab for the
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is …

Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019

R Ganesh, LM Philpot, DM Bierle… - The Journal of …, 2021 - academic.oup.com
Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild
to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the …

Monoclonal antibody therapy for COVID-19 in solid organ transplant recipients

ZA Yetmar, E Beam, JC O'Horo… - Open forum …, 2021 - academic.oup.com
Background Bamlanivimab and casirivimab-imdevimab are authorized for emergency use
treatment of mild to moderate coronavirus disease 2019 (COVID-19) in patients at high risk …

Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19

JD Coffey, LA Christopherson, AE Glasgow… - npj Digital …, 2021 - nature.com
Established technology, operational infrastructure, and nursing resources were leveraged to
develop a remote patient monitoring (RPM) program for ambulatory management of patients …

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

R Ganesh, CF Pawlowski, JC O'Horo… - The Journal of …, 2021 - Am Soc Clin Investig
BACKGROUND Clinical data to support the use of bamlanivimab for the treatment of
outpatients with mild to moderate coronavirus disease-19 (COVID-19) are needed …

A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the Mayo Clinic model

RR Razonable, NCE Aloia, RJ Anderson, G Anil… - Mayo Clinic …, 2021 - Elsevier
The administration of spike monoclonal antibody treatment to patients with mild to moderate
COVID-19 is very challenging. This article summarizes essential components and processes …

PROMIS scales for assessment of persistent post-COVID symptoms: a cross sectional study

R Ganesh, AK Ghosh, MA Nyman… - Journal of Primary …, 2021 - journals.sagepub.com
Objective Persistent post-COVID symptoms are estimated to occur in up to 10% of patients
who have had COVID-19. These lingering symptoms may persist for weeks to months after …

Association of a remote patient monitoring (RPM) program with reduced hospitalizations in cancer patients with COVID-19

JC Pritchett, BJ Borah, AP Desai, Z Xie… - JCO Oncology …, 2021 - ascopubs.org
PURPOSE: The goal of this study was to assess the impact of an interdisciplinary remote
patient monitoring (RPM) program on clinical outcomes and acute care utilization in cancer …

Breakthrough COVID‐19 after SARS‐CoV‐2 vaccination in solid organ transplant recipients: an analysis of symptomatic cases and monoclonal antibody therapy

ZA Yetmar, E Bhaimia, DM Bierle… - Transplant Infectious …, 2022 - Wiley Online Library
Background Solid organ transplant (SOT) recipients are at increased risk for complications
from SARS‐CoV‐2 infection. Little is known regarding clinical course and outcomes of …

A scalable framework for telehealth: the Mayo Clinic Center for Connected Care response to the COVID-19 pandemic

TC Haddad, RN Blegen, JE Prigge, DL Cox… - Telemedicine …, 2021 - liebertpub.com
Background: The Mayo Clinic Center for Connected Care has an established organizational
framework for telehealth care delivery. It provides patients, consumers, care teams, and …